News
What you need to know about Moderna’s new COVID vaccine, just approved by the FDA
Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID vaccine, but only for specific populations: all adults 65 and over and those between 12 and 64 with at least one underlying risk factor as defined by the Centers for Disease Control and Prevention.
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Moderna has announced FDA approval for its new COVID-19 vaccine, mNexspike (mRNA-1283). This next-generation shot targets a ...
Trump HHS ends nearly $1 billion in funding to Moderna for mRNA bird flu vaccines, citing safety concerns and lack of ...
The HHS terminated funding for for Moderna's avian influenza vaccine due to safety concerns with mRNA vaccines.
H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna’s award ...
KEY TAKEAWAYS U.S. equities were mixed at midday after China accused the U.S. of violating a trade deal the two countries ...
Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...
The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback